2022 Help me understand this report
Renal cell carcinoma with early skin metastasis and partial response on tyrosine kinase inhibitor: A case report
Search citation statements
Paper Sections
Select...
1
Citation Types
0
1
0
Year Published
2023
2023
Publication Types
Select...
1
Relationship
0
1
Authors
Journals
Cited by 1 publication
(1 citation statement)
References 6 publications
0
1
0
“…Some studies described the efficacy of targeted therapies with tyrosine kinase inhibitors in the management of SRCCs. 8 Despite treatment, the prognosis of metastatic SRCCs remains unfavorable, with an increased risk of recurrence and metastasis. The median overall survival ranges from 6 to 13 months.…”
Section: Discussionmentioning
confidence: 99%
“…Some studies described the efficacy of targeted therapies with tyrosine kinase inhibitors in the management of SRCCs. 8 Despite treatment, the prognosis of metastatic SRCCs remains unfavorable, with an increased risk of recurrence and metastasis. The median overall survival ranges from 6 to 13 months.…”
Section: Discussionmentioning
confidence: 99%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
